Insider Transactions Reported by 21 Insiders of TScan Therapeutics, Inc.

Symbol
TCRX on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

TScan Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Lynx1 Capital Management LP 10%+ Owner $37,208,412 +$3,252,079 +9.6% 19 Dec 2025
EcoR1 Capital, LLC 10%+ Owner $24,842,500 26 May 2023
Christoph H. Westphal 10%+ Owner $10,898,266 20 Jul 2021
Timothy J. Barberich Director $498,271 18 Dec 2023
Barbara Klencke Director $370,300 30 Jun 2025
David P. Southwell Chief Executive Officer, Director 02 Feb 2023
BAKER BROS. ADVISORS LP Director 30 Jun 2025
Katina Dorton Director 30 Jun 2025
Gavin MacBeath Chief Executive Officer, Director 20 Jan 2026
Zoran Zdraveski Exhibit List - Exhibit 24 - Power of Attorney; Chief Legal and Strategy Officer 20 Jan 2026
Leiden Dworak Principal Accounting Officer and Vice President, Finance 20 Jan 2026
Ittai Harel Director 01 Jun 2022
Stephen R. Biggar Director 15 Jul 2021
Brian M. Silver Chief Financial Officer 13 Jun 2023
William Desmarais Chief Business Officer 25 Jul 2022
Gabriela Gruia Director 30 Jun 2025
Debora Barton Chief Medical Officer 13 Jun 2023
Keith Woods Director 30 Jun 2025
Jason Amello Chief Financial Officer 20 Jan 2026
Garry A. Nicholson Director 30 Jun 2025
Chrystal Louis Chief Medical Officer 20 Jan 2026

Recent Insider Transactions by Companies or Individuals for TScan Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Jason Amello TCRX Stock Option (Right to Buy) Award 350,000 350,000 20 Jan 2026 Direct
Gavin MacBeath TCRX Stock Option (Right to Buy) Award 1,165,000 1,165,000 20 Jan 2026 Direct
Leiden Dworak TCRX Stock Option (Right to Buy) Award 100,000 100,000 20 Jan 2026 Direct
Chrystal Louis TCRX Stock Option (Right to Buy) Award 420,000 420,000 20 Jan 2026 Direct
Zoran Zdraveski TCRX Stock Option (Right to Buy) Award 350,000 350,000 20 Jan 2026 Direct
Lynx1 Capital Management LP TCRX Common Stock Purchase 0.08% $5,602 $0.8989 6,232 8,019,148 23 Dec 2025 See footnote
Lynx1 Capital Management LP TCRX Common Stock Purchase 0.95% $67,950 $0.9000 75,500 8,012,916 22 Dec 2025 See footnote
Lynx1 Capital Management LP TCRX Common stock, $0.0001 par value per share ("Common Stock") Purchase 1.02% $71,974 $0.8989 80,069 7,937,416 19 Dec 2025 See footnote
Baker Bros. Advisors Lp TCRX Non- Qualified Stock Option (right to buy) Award 134,000 67,000 30 Jun 2025 See Footnotes
Barbara Klencke TCRX Stock Option (Right to Buy) Award 67,000 67,000 30 Jun 2025 Direct
Garry A. Nicholson TCRX Stock Option (Right to Buy) Award 67,000 67,000 30 Jun 2025 Direct
Keith Woods TCRX Stock Option (Right to Buy) Award 67,000 67,000 30 Jun 2025 Direct
Katina Dorton TCRX Stock Option (Right to Buy) Award 67,000 67,000 30 Jun 2025 Direct
Gabriela Gruia TCRX Stock Option (Right to Buy) Award 67,000 67,000 30 Jun 2025 Direct
Lynx1 Capital Management LP TCRX Common Stock Purchase 17.8% $1,440,000 $1.20 1,200,000 7,946,141 20 May 2025 See footnote
Lynx1 Capital Management LP TCRX Common stock, $0.0001 par value per share ("Common Stock") Purchase 25.9% $1,666,553 $1.20 1,388,794 6,746,141 19 May 2025 See footnote
* An asterisk sign (*) next to the price indicates that the price is likely invalid.